Drugs /

iopamidol

Back to Drugs List

Overview

NCI Definition [1]:
An organic iodine compound and used as a non-ionic water soluble radiographic contrast medium. Iopamidol blocks x-rays as they pass through the body, thereby allowing body structures not containing iodine to be visualized. The degree of opacity produced by iopamidol is directly proportional to the total amount of the iodinated contrast agent in the path of the x-rays. The visualization of body structures is dependent upon the distribution and elimination of iopamidol.

Clinical Trials

View Clinical Trials for iopamidol

Iopamidol has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating iopamidol, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open).

ER Expression, ER Positive, and FGFR1 Mutation are the most frequent biomarker inclusion criteria for iopamidol clinical trials.

Breast carcinoma, prostate adenocarcinoma, and renal cell carcinoma are the most common diseases being investigated in iopamidol clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Iopamidol
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating iopamidol and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
1,3-benzenedicarboxamide, n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-, (s)-n,n'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide, isovue, niopam, solutrast
NCIT ID [1]:
C47567

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.